

What: Operations Committee Meeting
Date & Time: April 25, 2024; 12:30-1:30 p.m. PT
Location: Zoom

This meeting will take place solely by webinar. To register for this meeting, please visit:
https://us02web.zoom.us/webinar/register/WN_LK0mnKeiQ4GxS65Zf9TfDw

Notice: The meeting may be recorded for the benefit of the minute-taker. The WVA intends to delete the recording after the minutes are approved.

Agenda

Approx. Time	*	Page	Topic/[Anticipated Action]	Presented by:
12:30-12:35 p.m.			1. Introductions & Agenda Review a. Notice of Recording b. Survey of Other Topics	J. Zell
12:35-12:40 p.m.	*	Pg. 2-3	2. Action Items a. Vote to Approve Operations Committee Minutes - October 26, 2023	J. Zell
12:40-1:00 p.m.	* *	Pg. 4-16 Pg. 17-26	3. Assessment Grid 2024-25 a. Process and Communications Plan b. Vote to Finalize 2024-25 Assessment Grid	J. Zell / P. Miller
1:00-1:25 p.m.			4. Operational Updates a. Non-Traditional Provider Outreach b. Inpatient Hospital DBA Update c. Future Steps d. Vaccine Pipeline - PENBRAYA	J. Zell / P. Miller / A. Ithal
1:25-1:30 p.m.			5. Other Matters from Committee Members	Any
1:30 p.m.			6. Closing	J. Zell

*Indicates agenda item attached
Red text indicates an action item

**Washington Vaccine Association
Operations Committee Meeting
October 26, 2023; 12:30-1:30 p.m. PT**

I. Attendance. Participating in all or part of the meeting by telephone were the following individuals:

7 <u>Committee Members</u>	18 Cheryl Rairigh, Regence
8 Michelle Baker, Zenith	19 Jennifer Simonsen, Kaiser
9 Diana Baxter, Cambia	20
10 Tracey Cardillo, Cigna	21 <u>WVA</u>
11 Tiffany Conley, Regence	22 Julia G. Zell, Esq., Executive Director, Chair
12 Delphia Dent Leffew, Cigna	23 Cheri Cagle, Stakeholder Liaison
13 Cathy Falanga, Aetna	24
14 Tawnya Flyberg, Premera	25 <u>Helms & Company, Inc.</u>
15 Janel Jorgenson, Washington Department of Health	26 Patrick Miller, MPH, Administrative Director
16 Kara Manley, United	27 Ashley Ithal, MPH, Project Support Leader
17 Valerie Oliver, Premera	28 Leslie Walker, CPA, Mason+Rich, PA

I. Summary of Actions Taken and/or Recommended

Actions Taken (votes adopted)

- i. To approve April 25, 2023, meeting minutes.
- ii. To approve future Assessment Grid additions.

II. Welcome and Introductions

At 12:32 p.m., Ms. Zell called the meeting to order and provided a notice of recording.

III. Calendar Consent Items

Ms. Zell asked for a motion to approve the April 25, 2023 meeting minutes. Upon motion duly made and seconded, it was unanimously

VOTED: To approve April 25, 2023 meeting minutes.

IV. Operations Updates

COVID Implementation

Ms. Zell gave an update on the COVID commercialization and stated that initial concerns of the dosage-based assessment process have been alleviated after a review of payer data. Mr. Miller reported that for the most part, COVID DBAs are being submitted with the correct grid amounts. Mr. Miller stated that there are a few payers with lower-than-expected DBA volumes and he has reached out to them. He stated that the first COVID-related mailing was sent out in mid-September to providers and payers, and a second provider mailing was sent in mid-October.

RSV (nirsevimab) Funding

Ms. Zell reminded the Committee that in late September the WVA Board approved the use of reserve funds for the state's purchase of the new RSV monoclonal antibody, nirsevimab. To be able to assess for nirsevimab, the WVA is joining with the Department of Health to pursue a technical "fix" to the Association's enabling statute to update the definition of "vaccine." To advance this work, the WVA has engaged a lobbyist. Mr. Miller stated that the WVA should know by the end of March 2024 whether the statute has been changed. He provided an overview of the WA Department of Health's (DOH) proposed RSV utilization projections which vary from approximately \$10M-20M/year based on projected uptake scenarios.

Future Assessment Grids/New Vaccine Pipeline

66 Mr. Miller reviewed the costs of vaccines added in the past year and stated that the costs are much higher than
67 historically seen which will have impacts on future assessment rates. Mr. Miller reported that Abrysvo™ (for maternal
68 RSV), Penbraya™ (for Meningococcal B), and Jynneos® (for Mpox) have been both FDA approved and ACIP VFC
69 recommended. It is anticipated that pricing will be known by the end of the year so that they may be added to the grid
70 for early 2024. Ms. Zell added that ideally the WVA would add future off cycle grid additions in January of each year,
71 and continue with the annual grid updates on July 1. Mr. Miller added that the July 2024 grid may see up to a 30%
72 rate increase to build back reserves. He reported that modeling has begun using known assumptions.

73
74 Mr. Miller stated that the WVA is assembling a taskforce to determine the best way for hospitals to bill DBAs for
75 nirsevimab. Ms. Dent and Ms. Manley volunteered to join the taskforce. Ms. Zell stated that if others are interested,
76 please reach out to her.

77
78 Ms. Jorgenson provided an update on nirsevimab ordering. There were 135 providers who placed orders before CDC
79 shut down ordering due to supply chain issues. The CDC is currently distributing nirsevimab based on allocations to
80 those states that have either not ordered nirsevimab or ordered a low supply.

81
82 Ms. Zell asked for a motion to approve the addition of Abrysvo™ (for maternal RSV for those under 19), Penbraya™
83 (for Meningococcal B), and Jynneos® (for Mpox for those under 19) to the Assessment Grid. Discussion occurred and
84 a minor correction was made to the vote. Upon motion duly made and seconded, it was unanimously

85
86 **VOTED: Vote to approve assessment grid additions of Abrysvo™ (for maternal RSV for those under**
87 **19), Penbraya™ (for Meningococcal B), and Jynneos® (for Mpox for those under 19) with corrections**
88 **at the meeting.**

89
90 **V. Closing**

91
92 Ms. Zell thanked everyone for their input and guidance today, and the meeting was adjourned at 1:22 pm PT.



FY2025 Vaccine Assessment Grid Operations Committee


April 25, 2024

Discussion Topics

- Process Timeline
- Integrated Approach
- Cash Projection Model
- Assessment Grid



2024-25 Budget & Vaccine Grid Development Process






Integrated Approach


2024-25 Vaccine Assessment Grid Goal:
Build cash reserves through multi-year, incremental Vaccine Assessment Grid increases.

The Vaccine Assessment Grid is built upon the Cash Flow Model and the Administrative Budget.







Weighted Average Grid Amount Vs. Weighted Average Private Sector Price – FY2017-FY2027



Cash Ending Balance – Actual and Projected




Historic Cash High and Low Points



Collections and DOH Remittances

**Total Vaccine Collections and Vaccine Remittances to State of WA
March 2023- March 2024**





WA DOH FY25 Assessment Grid Changes

1. Additions

- a. Meningococcal B & Conjugate Penbraya™
- b. Respiratory Syncytial Virus Beyfortus
- c. Smallpox & Mpox - Age 18 Only JYNNEOS®


2. Changes

- a. Influenza quadravalent moving to trivalent
- b. Expectation that current COVID-19 vaccines will expire in early June 2024 with fall COVID-19 vaccine decisions made by CDC ACIP in late June

3. Retired

- a. DT Pediatric
- b. Menactra®

Weighted CDC Contract Price Increases



Model Summary

Adjustment Variables	Assumptions			
	FY2024 Projected	FY2025	FY2026	FY2027
Assessment Grid as Percent of Prior Year	110.0%	119%	100%	100%
TRICARE Surcharge	2.5%	2.5%	2.5%	2.5%
DOH Indirect Charge	1.4%	1.4%	1.4%	1.4%
DOH Cost Recovery Fee (2.8% Cap)	1.4%	1.8%	1.8%	1.8%
Vaccine Wastage	2.5%	2.4%	2.4%	2.4%
Denials	7.0%	7.0%	7.0%	7.0%
Denial Recoveries	1.0%	1.0%	1.0%	1.0%
Administrative Budget	\$2.19M	\$2.51M	\$2.40M	\$2.33M
Cash Generated / (Used)	(\$21.6M)	\$16.5M	\$12.4M	\$ 6.5M
Year End Balance	\$22.9M	\$39.5M	\$51.9M	\$58.4M
CDC Vaccine Purchase Price Increase	4.6%	3.1%	5.0%	5.0%

Assessment Grid



April 16, 2024 DRAFT

2024-25 Vaccine Assessment Grid

PRINTABLE ASSESSMENT GRID TAB

Washington Vaccine Association Assessment Grid FOR ALL CLAIMS WITH A DATE OF SERVICE ON OR AFTER JULY 1, 2024.		For Dosage-Based Assessment (DBA) Billing Used for Commercially Insured Patients Under the Age of 19.					
Please note that this WVA Assessment Grid, effective July 1, 2024, replaces the grid last updated on July 1, 2023. The grid lists vaccines and their corresponding CPT codes that are part of the							
CPT Code	NDC Code / Packaging	CPT Code Description	Tradename	WVA Assessment Amount Per Dose from 07/01/2023 to 06/30/2024	For Reference: CDC Private Sector Cost Per Dose 04/01/2024	WVA Assessment Amount Per Dose from 07/01/2024 to 06/30/2025	Percent Change 07/01/2023 to 07/01/2024
Hepatitis A							
90633	58160-0825-52 (10 pack – 1 dose syringe)	Hepatitis A vaccine (HepA), pediatric/adolescent dosage-2 dose schedule, for intramuscular use	Havrix®	\$22.79	\$38.01	\$29.54	29.6%
	00006-4095-02 (10 pack – 1 dose syringe)		Vaqta®	\$37.74	\$37.74		
Hepatitis B							
90744	00006-4981-00 (10 pack – 1 dose vial)	Hepatitis B vaccine (HepB), pediatric/adolescent dosage, 3 dose schedule, for intramuscular use	Recombivax HB®	\$13.79	\$27.12	\$18.19	31.9%
	00006-4093-02 (10 pack – 1 dose syringe)						
	58160-0820-52 (10 pack – 1 dose syringe)		Engerix B®	\$28.42	\$28.42		
Rotavirus							
90680	00006-4047-41 (10 pack – 1 dose tube)	Rotavirus vaccine, pentavalent (RV5), 3 dose schedule, live, for oral use	RotaTeq®	\$79.24	\$95.96	\$86.67	9.4%
	00006-4047-20 (25 pack – 1 oral dose)						
90681	58160-0854-52 (10 pack – 1 dose vial)	Rotavirus vaccine, human, attenuated (RV1), 2 dose schedule, live, for oral use	Rotarix®	\$107.67	\$138.74	\$115.56	7.3%
	58160-0740-21 (10 pack – 1 oral dose)				\$138.74		
DTaP							
90696	58160-0812-52 (10 pack – 1 dose syringe)	Diphtheria, tetanus toxoids, acellular pertussis vaccine and inactivated poliovirus vaccine (DTaP-IPV), when administered to children 4 through 6 years of age, for intramuscular use	Kinrix®	\$46.12	\$61.08	\$50.29	9.0%
	49281-0562-10 (10 pack – 1 dose vial)		Quadracel™		\$62.21		
	49281-0564-10 (10 pack – 1 dose vial)						
	49281-0564-15 (10 pack – 1 dose syringe)						



Stay connected.

Sign up to stay informed by going to:

www.wavaccine.org/contact/

info@wavaccine.org

Ph 888-928-2224

Fax 888-928-2242

Mailing Address:

PO Box 94002

Seattle, WA 98124-9402

www.wavaccine.org



PRINTABLE ASSESSMENT GRID TAB

Washington Vaccine Association Assessment Grid
FOR ALL CLAIMS WITH A DATE OF SERVICE ON OR AFTER JULY 1, 2024.

For Dosage-Based Assessment (DBA) Billing Used for Commercially Insured Patients Under the Age of 19.

Please note that this **WVA Assessment Grid, effective July 1, 2024, replaces the grid last updated on July 1, 2023.** The grid lists vaccines and their corresponding CPT codes that are part of the dosage-based assessment (DBA) process for providers, health insurance carriers, and third party administrators. There are other childhood vaccines (and corresponding CPT codes) that are not included in the DBA process and, therefore, no assessment is needed. The availability of specific vaccine brands are determined by the manufacturer and not all brands of flu vaccine are offered through the Childhood Vaccine Program (CVP). **The PURPLE COLUMN is the assessment amount per dose as of July 1, 2024.**

CPT Code	NDC Code / Packaging	CPT Code Description	Tradename	WVA Assessment Amount Per Dose from 07/01/2023 to 06/30/2024	For Reference: CDC Private Sector Cost Per Dose 04/01/2024	WVA Assessment Amount Per Dose from 07/01/2024 to 06/30/2025	Percent Change 07/01/2023 to 07/01/2024
Hepatitis A							
90633	58160-0825-52 (10 pack – 1 dose syringe)	Hepatitis A vaccine (HepA), pediatric/adolescent dosage-2 dose schedule, for intramuscular use	Havrix®	\$22.79	\$38.01	\$29.54	29.6%
	00006-4095-02 (10 pack – 1 dose syringe)		Vaqta®		\$37.74		
Hepatitis B							
90744	00006-4981-00 (10 pack – 1 dose vial)	Hepatitis B vaccine (HepB), pediatric/adolescent dosage, 3 dose schedule, for intramuscular use	Recombivax HB®	\$13.79	\$27.12	\$18.19	31.9%
	00006-4093-02 (10 pack – 1 dose syringe)		Engerix B®		\$28.42		
	58160-0820-52 (10 pack – 1 dose syringe)						
Rotavirus							
90680	00006-4047-41 (10 pack – 1 dose tube)	Rotavirus vaccine, pentavalent (RV5), 3 dose schedule, live, for oral use	RotaTeq®	\$79.24	\$95.96	\$86.67	9.4%
	00006-4047-20 (25 pack – 1 oral dose)						
90681	58160-0854-52 (10 pack – 1 dose vial)	Rotavirus vaccine, human, attenuated (RV1), 2 dose schedule, live, for oral use	Rotarix®	\$107.67	\$138.74	\$115.56	7.3%
	58160-0740-21 (10 pack – 1 oral dose)				\$138.74		

DRAFT FOR APPROVAL 04.18.2024



Intentionally Left Blank

CPT Code	NDC Code / Packaging	CPT Code Description	Tradename	WVA Assessment Amount Per Dose from 07/01/2023 to 06/30/2024	For Reference: CDC Private Sector Cost Per Dose 04/01/2024	WVA Assessment Amount Per Dose from 07/01/2024 to 06/30/2025	Percent Change 07/01/2023 to 07/01/2024
DTaP							
90696	58160-0812-52 (10 pack – 1 dose syringe)	Diphtheria, tetanus toxoids, acellular pertussis vaccine and inactivated poliovirus vaccine (DTaP-IPV), when administered to children 4 through 6 years of age, for intramuscular use	Kinrix®	\$46.12	\$61.08	\$50.29	9.0%
	49281-0562-10 (10 pack – 1 dose vial)		Quadracel™		\$62.21		
	49281-0564-10 (10 pack – 1 dose vial)						
	49281-0564-15 (10 pack – 1 dose syringe)						
90697	63361-0243-15 (10 pack – 1 dose syringe)	Diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus, Haemophilus b conjugate (meningococcal protein conjugate), and Hepatitis B (recombinant) vaccine	Vaxelis™	\$91.72	\$150.85	\$125.19	36.5%
	63361-0243-10 (10 pack – 1 dose vial)						
90698	49281-0511-05 (5 pack – 1 dose vial)	Diphtheria, tetanus toxoids, acellular pertussis vaccine, Haemophilus influenzae type b, and inactivated poliovirus vaccine, (DTaP-IPV/Hib), for intramuscular use	Pentacel®	\$68.13	\$114.52	\$95.23	39.8%
90700	49281-0286-10 (10 pack – 1 dose vial)	Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), when administered to individuals younger than seven years, for intramuscular use	Daptacel®	\$20.49	\$29.31	\$22.47	9.7%
	58160-0810-52 (10 pack – 1 dose syringe)		Infanrix®		\$28.80		
90723	58160-0811-52 (10 pack – 1 dose syringe)	Diphtheria, tetanus toxoids, acellular pertussis vaccine, hepatitis B, and inactivated poliovirus vaccine (DTaP-HepB-IPV), for intramuscular use	Pediarix®	\$67.07	\$97.97	\$71.76	7.0%
Tdap							



2024-25 Vaccine Assessment Grid

90714	49281-0215-15 (10 pack – 1 dose syringe)	Tetanus and diphtheria toxoids adsorbed (Td), preservative free, when administered to individuals 7 years or older, for intramuscular use	Tenivac®	\$18.06	\$37.10	\$25.68	42.2%
	49281-0215-10 (10 pack – 1 dose vial)						
	13533-0131-01 (10 pack – 1 dose vial)		TDVAX™		\$27.99		
90715	58160-0842-52 (10 pack – 1 dose syringe)	Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use	Boostrix®	\$36.00	\$47.39	\$39.59	10.0%
	49281-0400-10 (10 pack – 1 dose vial)		Adacel®		\$47.83		
	49281-0400-20 (5 pack – 1 dose syringe)				\$47.83		

CPT Code	NDC Code / Packaging	CPT Code Description	Tradename	WVA Assessment Amount Per Dose from 07/01/2023 to 06/30/2024	For Reference: CDC Private Sector Cost Per Dose 04/01/2024	WVA Assessment Amount Per Dose from 07/01/2024 to 06/30/2025	Percent Change 07/01/2023 to 07/01/2024
Haemophilus Influenzae							
90647	00006-4897-00 (10 pack – 1 dose vial)	Haemophilus influenzae type b vaccine (Hib), PRP-OMP conjugate, 3 dose schedule, for intramuscular use	PedvaxHIB®	\$14.89	\$29.71	\$17.12	15.0%
90648	49281-0545-03 (5 pack – 1 dose vial)	Haemophilus influenzae type b vaccine (Hib), PRP-T conjugate, 4 dose schedule, for intramuscular use	ActHIB®	\$10.41	\$12.92	\$10.72	3.0%
	58160-0726-15 (10 pack – 1 dose vial)		Hiberix®		\$12.80		
	58160-0818-11 (10 pack – 1 dose vial)						
Pneumococcal							
90670	00005-1971-02 (10 pack – 1 dose syringe)	Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use	Pprevnar 13™	\$159.32	\$226.43	\$216.14	35.7%
90677	00005-2000-10 (10 pack – 1 dose syringe)	Pneumococcal conjugate vaccine, 20 valent (PCV20), for intramuscular use	Pprevnar 20™	\$159.32	\$261.56	\$216.14	35.7%
90671	00006-4329-03 (10 pack – 1 dose syringe)	Pneumococcal conjugate PCV15, polysaccharide CRM197 conjugate, adjuvant, PF	Vaxneuvance™	\$182.07	\$222.55	\$194.81	7.0%



2024-25 Vaccine Assessment Grid

90732	00006-4837-03 (10 pack – 1 dose syringe)	Pneumococcal polysaccharide vaccine, 23-valent (PPSV23), adult or immunosuppressed patient dosage, when administered to individuals 2 years or older, for subcutaneous or intramuscular use	Pneumovax®23	\$65.76	\$117.08	\$93.67	42.4%
Inactivated Poliovirus							
90713	49281-0860-10 (10 dose vial)	Poliovirus vaccine, inactivated (IPV), for subcutaneous or intramuscular use	IPOL®	\$15.29	\$42.64	\$17.12	12.0%
MMR							
90707	00006-4681-00 (10 pack – 1 dose vial)	Measles, mumps and rubella virus vaccine (MMR), live, for subcutaneous use	M-M-R® II	\$23.95	\$92.49	\$27.82	16.2%
	58160-0824-15 (10 pack – 1 dose vial)		Priorix				
90710	00006-4171-00 (10 pack – 1 dose vial)	Measles, mumps, rubella, and varicella vaccine (MMRV), live, for subcutaneous use	ProQuad®	\$152.54	\$270.15	\$223.63	46.6%
Varicella							
90716	00006-4827-00 (10 pack – 1 dose vial)	Varicella virus vaccine (VAR), live, for subcutaneous use	Varivax®	\$121.31	\$174.32	\$150.87	24.4%
HPV							
90651	00006-4121-02 (10 pack – 1 dose syringe)	Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 2 or 3 dose schedule, for intramuscular use	Gardasil®9	\$207.99	\$287.54	\$215.02	3.4%

CPT Code	NDC Code / Packaging	CPT Code Description	Tradename	WVA Assessment Amount Per Dose from 07/01/2023 to 06/30/2024	For Reference: CDC Private Sector Cost Per Dose 04/01/2024	WVA Assessment Amount Per Dose from 07/01/2024 to 06/30/2025	Percent Change 07/01/2023 to 07/01/2024
Meningococcal B							
90620	58160-0976-20 (10 pack – 1 dose syringe)	Meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B (MenB-4C), 2 dose schedule, for intramuscular use	Bexsero®	\$132.92	\$190.26	\$179.76	35.2%
90621	00005-0100-10 (10 pack – 1 dose syringe)	Meningococcal recombinant lipoprotein vaccine, serogroup B (MenB-FHbp), 2 or 3 dose schedule, for intramuscular use	Trumenba®	\$126.69	\$178.95	\$145.52	14.9%
Meningococcal Conjugate							



2024-25 Vaccine Assessment Grid

90619	49281-0590-05 (5 pack – 1 dose vial)	Meningococcal polysaccharide (groups A, C, Y, W-135) tetanus toxoid conjugate vaccine .5mL dose, preservative free	MenQuadfi™	\$105.77	\$166.98	\$132.68	25.4%
90734	58160-0827-30 (10 pack – 1 dose vial)	Meningococcal conjugate vaccine, serogroups A, C, Y and W-135, quadrivalent (MCV4 or MenACWY), for intramuscular use	Menveo® One Vial	\$105.77	\$157.35	\$126.26	19.4%
	Menveo® Two Vial						
Meningococcal B & Conjugate							
90623	00069-0600-01 NEW 6.1.2024 (1 pack – 1 dose vial)	Meningococcal pentavalent vaccine, conjugated Men A, C, W, Y- tetanus toxoid carrier, and Men B-FHbp, for intramuscular use	PENBRAYA™	n/a	\$230.75	\$207.67	n/a
	00069-0600-05 NEW 6.1.2024 (5 pack – 1 dose vial)			n/a			
RSV - Respiratory Syncytial Virus							
90380	49281-0575-15 NEW: 7.1.2024 (5 pack – 1 dose syringe)	Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for intramuscular use	Beyfortus™ (50mg)	n/a	\$519.75	\$450.00	n/a
90381	49281-0574-15 NEW 7.1.2024 (5 pack – 1 dose syringe)	Respiratory syncytial virus, monoclonal antibody, seasonal dose; 1.0 mL dosage, for intramuscular use	Beyfortus™ (100mg)	n/a	\$519.75	\$450.00	n/a
90678	00069-0344-01 NEW 1.1.2024 (1 pack – 1 dose vial)	RSV, bivalent, protein subunit RSVpreF, diluent reconstituted, 0.5 mL, PF	ABRYSVO™	\$265.50	\$295.00	\$265.50	n/a
Smallpox & Mpox - Age 18 Only (Ordering Expected to Begin in August 2024)							
90611	50632-0001-03 NEW: 8.1.2024 (10 pack – 1 dose vial)	Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, non-replicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous use	JYNNEOS®	n/a	n/a	\$275.40	n/a
Influenza							
Note: All influenza codes for the period will have a Grid amount of \$18.00. A separate Grid update will be sent during the summer of 2024 once the trivalent CPT, NDC, and descriptions are available for the fall 2024/winter 2025 season.				n/a	\$24.70	\$18.00	
COVID-19							
Note: All COVID-19 codes for the period will have a Grid amount of \$113.00. A separate Grid update will be sent during the summer of 2024 once the CDC's ACIP determines the strain for the fall 2024/winter 2025 season and the CPT, NDC, and descriptions are available.				\$105.00	n/a	\$113.00	7.6%

NOTE: The WVA reserves the right to modify the Assessment Grid in effect at any time with Board approval and appropriate notification of payers.

To ensure proper DBA submission and carrier/TPA remittance to the WVA, providers should check the:

- **Date of service** to ensure the correct Grid year is being used;
- **CPT code** to ensure it is a valid code for the date of service (*see **note** below); and
- **Assessment Grid amount** to ensure proper DBA submission and carrier/TPA remittance to the WVA.

*Please note: Sometimes vaccine material is still viable and can be administered, even if it has been discontinued from prior Grids and is not shown on the current Grid.

If the CPT code is not offered on the current Grid, providers should check the legacy information at the end of the grid document to determine if a prior Grid amount **DRAFT APR 17, 2024 V2;**



should be billed on the DBA. Please validate the date of service and the legacy Grid year when selecting the Grid amount.

DISCONTINUED PEDIATRIC INFLUENZA NDC CODES AS OF JUNE 30, 2024

CPT Code	NDC Code / Packaging	CPT Code Description	Tradename
90672	66019-0310-10 (10 pack- 1 dose sprayer (Intranasal))	Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use	FluMist® Quadrivalent
90674	70461-0323-03 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use	Flucelvax® Quadrivalent
90686	19515-0814-52 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	FluLaval® Quadrivalent
	49281-0423-50 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	Fluzone® Quadrivalent SYR
90688	49281-0639-15 (10 dose vial)	Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use	Fluzone® Quadrivalent MDV

DISCONTINUED PEDIATRIC INFLUENZA NDC CODES AS OF JUNE 30, 2023

CPT Code	NDC Code / Packaging	CPT Code Description	Tradename
90686	19515-0808-52 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	FluLaval® Quadrivalent
	49281-0422-50 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	Fluzone® Quadrivalent SYR
90688	49281-0637-15 (10 dose vial)	Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use	Fluzone® Quadrivalent MDV
90672	66019-0309-10 (10 pack- 1 dose sprayer (Intranasal))	Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use	FluMist® Quadrivalent
90674	70461-0322-03 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use	Flucelvax® Quadrivalent

Intentionally Left Blank



DISCONTINUED PEDIATRIC INFLUENZA NDC CODES AS OF JUNE 30, 2022			
CPT Code	NDC Code / Packaging	CPT Code Description	Tradename
90686	19515-0818-52 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	FluLaval® Quadrivalent
	49281-0421-50 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	Fluzone® Quadrivalent SYR
90688	49281-0635-15 (10 dose vial)	Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use	Fluzone® Quadrivalent MDV
90672	66019-0308-10 (10 pack- 1 dose sprayer (Intranasal))	Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use	FluMist® Quadrivalent
90674	70461-0321-03 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (cIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use	Flucelvax® Quadrivalent
DISCONTINUED PEDIATRIC INFLUENZA NDC CODES AS OF JUNE 30, 2021			
CPT Code	NDC Code / Packaging	CPT Code Description	Tradename
90686	19515-0816-52 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	FluLaval® Quadrivalent
	49281-0420-50 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	Fluzone® Quadrivalent SYR
90688	49281-0635-15 (10 dose vial)	Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use	Fluzone® Quadrivalent MDV
90672	66019-0308-10 (10 pack- 1 dose sprayer (Intranasal))	Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use	FluMist® Quadrivalent
90674	70461-0321-03 (10 pack - 1 dose syringe)	Influenza virus vaccine, quadrivalent (cIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use	Flucelvax® Quadrivalent
DISCONTINUED PEDIATRIC INFLUENZA NDC CODES AS OF JUNE 30, 2020			
CPT Code	NDC Code / Packaging	CPT Code Description	Tradename
90686	19515-0906-52 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	FluLaval® Quadrivalent
	49281-0419-50 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	Fluzone® Quadrivalent SYR



90672	66019-0306-10 (10 pack- 1 dose sprayer (Intranasal))	Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use	FluMist® Quadrivalent
90688	49281-0631-15 (10 dose vial)	Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use	Fluzone® Quadrivalent MDV
90674	70461-0319-03 (10 pack - 1 dose syringe)	Influenza virus vaccine, quadrivalent (cclIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use	Flucelvax® Quadrivalent

DISCONTINUED CPT OR NDC CODES FROM JULY 1, 2023 ASSESSMENT GRID

CPT Code	NDC Code / Packaging	July 1, 2023 Grid CPT Code Description	Tradename	WVA Assessment Amount per dose as of 7/1/2023
91320	00069-2362-10 (10 pack –1 dose vial)	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	COMIRNATY® (Pfizer)	\$105.00
90702	49281-0225-10 (10 pack – 1 dose vial)	Diphtheria and tetanus toxoids adsorbed (DT) when administered to individuals younger than 7 years, for intramuscular use	DT (pediatric)	\$65.55
90715	58160-0842-11 (10 pack – 1 dose vial)	Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use	Boostrix®	\$36.00
90734	49281-0589-05 (5 pack – 1 dose vial)	Meningococcal conjugate vaccine, serogroups A, C, Y and W-135, quadrivalent (MCV4 or MenACWY), for intramuscular use	Menactra®	\$105.77

DISCONTINUED CPT OR NDC CODES FROM JULY 1, 2022 ASSESSMENT GRID

CPT Code	NDC Code / Packaging	July 1, 2022 Grid CPT Code Description	Tradename	WVA Assessment Amount per dose as of 7/1/2022
NONE				N/A

DISCONTINUED CPT OR NDC CODES FROM JULY 1, 2020 ASSESSMENT GRID

DISCONTINUED CPT OR NDC CODES FROM JULY 1, 2020 ASSESSMENT GRID				
---	--	--	--	--

July 1, 2021 Grid				
CPT Code	NDC Code / Packaging	CPT Code Description	Tradename	WVA Assessment Amount per dose as of 7/1/2021
90696	58160-0812-11 (10 pack – 1 dose vial)	Diphtheria, tetanus toxoids, acellular pertussis vaccine and inactivated poliovirus vaccine (DTaP-IPV), when administered to children 4 through 6 years of age, for intramuscular use	Kinrix®	\$41.93
90698	49281-0510-05 (5 pack – 1 dose vial)	Diphtheria, tetanus toxoids, acellular pertussis vaccine, Haemophilus influenzae type b, and inactivated poliovirus vaccine, (DTaP-IPV/Hib), for intramuscular use	Pentacel®	\$61.94
90700	58160-0810-11 (10 pack – 1 dose vial)	Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), when administered to individuals younger than seven years, for intramuscular use	Infanrix®	\$18.63

Intentionally Left Blank

DISCONTINUED CPT OR NDC CODES FROM JULY 1, 2019 ASSESSMENT GRID				
July 1, 2019 Grid				
CPT Code	NDC Code / Packaging	CPT Code Description	Tradename	WVA Assessment Amount per dose as of 7/1/2019
90636	58160-0815-52 (10 pack – 1 dose syringe)	Hepatitis A and hepatitis B vaccine (HepA-HepB), adult dosage, for intramuscular use. (Age 18 only for CVP)	Twinrix®	\$67.29

DISCONTINUED CPT OR NDC CODES FROM JULY 1, 2018 ASSESSMENT GRID				
July 1, 2018 Grid				
CPT Code	NDC Code / Packaging	CPT Code Description	Tradename	WVA Assessment Amount per dose as of 7/1/2018



90685	49281-0518-25 (10 pack - 1 dose syringe)	Influenza virus vaccine, quadrivalent, split virus, preservative free, when administered to children 6 - 35 months of age, for intramuscular use (Code Price is per 0.25 mL dose)	Fluzone Pediatric Preservative Free (PF)	\$23.16
-------	--	---	---	---------

DISCONTINUED CPT OR NDC CODES FROM JULY 1, 2017 ASSESSMENT GRID				
CPT Code	NDC Code	July 1, 2017 Grid CPT Code Description	Trade Name(s)	WVA Assessment Amount per dose as of 7/1/2017
90644	58160-0801-11	Meningococcal conjugate vaccine, serogroups C & Y and Hemophilus influenza B vaccine (Hb-MenCY), 4 dose schedule, when administered to high risk children 2 - 15 months of age, for intramuscular use	MenHibrix	\$14.72
90649	00006-4045-41	Human Papilloma Virus (HPV) vaccine, types 6, 11, 16, 18 (quadrivalent), 3 dose schedule, for intramuscular use (Code Price is per dose = 0.5 mL)	Gardasil	n/a
90650	58160-0830-52	Human Papilloma virus (HPV) vaccine, types 16, 18, bivalent, 3 dose schedule, for intramuscular use (Code Price is per dose = 0.5 mL)	Cervarix	n/a
90743	00006-4981-00	Hepatitis B vaccine, adolescent dosage (2-dose schedule), for intramuscular use (Code price is per dose) (Recombivax HB 10mcg = one dose)	Recombivax HB	\$17.19
90685	49281-0517-25	Influenza virus vaccine, quadrivalent, split virus, preservative free, when administered to children 6 - 35 months of age, for intramuscular use (Code Price is per 0.25 mL dose)	Fluzone Pediatric Preservative Free (PF)	\$23.16
90687	49281-0517-25	Influenza virus vaccine, quadrivalent, split virus, when administered to children 6-35 months of age, for intramuscular use	Fluzone	\$18.47

DRAFT FOR APPROVAL 04-18-2024